Copyright © 2016 UCSD ADRC.
All rights reserved.

 

MCI Research Opportunities

 

The Shiley-Marcos Alzheimer’s Disease Research Center has a wide variety of opportunities for volunteers to participate in important research studies designed to discover ways to prevent, treat, and ultimately eradicate Alzheimer’s disease. We are recruiting diverse volunteers on an ongoing basis to learn more about memory and aging.

Research Registry

Are you interested in participating in a research study but don't currently see one that suits you? You can now join our Research Registry to be placed on a list for future studies. 

*Call the ADRC 858-822-4800 and ask for Christina Gigliotti, Ph.D. for more information on being added to the registry or to determine your eligibilty for any of our enrolling studies.

 

Currently Enrolling New Participants

 

Observational Studies

Memory Impaired Longitudinal Study

Clinical Trials

DISCOVER 
PI: Douglas Galasko, MD


CONTACT: Tracey Truscott, LCSW (858) 822-4800 or ttruscott@ucsd.edu (study coordinator, Helen Vanderswag, RN)


TIME INVOLVED: Up to two months and will require at least five study clinic visits including a three-day stay at the clinical research unit. Compensation will be provided to enrolled participants.


DESCRIPTION: Posiphen is an experimental drug de­veloped as an anti-amyloid medication that may delay Alzheimer’s disease (AD) onset or slow the progression of possible AD-related brain damage due to amyloid build­up. Participants in Discover will help researchers learn if the experimental drug is both safe and tolerated. This is a randomized, double-blind, placebo-controlled study with a 50/50 chance of receiving the experimental drug.


REQUIREMENTS: Age 55-85; diagnosis of MCI or mild Alzheimer’s disease; MMSE 24-30; study partner, MRI scan, lumbar puncture, willing to undergo extended stay in clinical research unit (2 nights).

To view a slideshow presentation for more information, click here

To view the study flyer, click here

 

EMERGE:  Biogen (BIIB037)

PI:  James Lohr, MD     

Contact: Lorraine Cheng, LOCHENG@ucsd.edu, (858) 775-8869

Time involved: 2 years

Description:  The purpose of this study is to evaluate the efficacy and safety of Aducanumab (BIIB037) in persons with early Alzheimer's disease.  Aducanumab is a human monoclonal antibody, and it is being evaluated to determine whether it can remove the amyloid plaques and slow the progression of symptoms in early AD.  

Requirements: Age 50-85; MMSE 24-30; study partner, PET and MRI scans, able to have monthly infusions

 

Other Research

Amy Jak, PhD is conducting a study with persons who have a diagnosis of MCI called: "Impact of Combined Behavioral Interventions on Cognitive Outcomes in MCI." Click here to read the study brochure. For more information or to participate contact aarauch@ucsd.edu or (858) 642-6375.

Research Registry

Are you interested in participating in a research study but don't currently see one that suits you? You can now join our Research Registry to be placed on a list for future studies. 

*Call the ADRC 858-822-4800 and ask for Tracey Truscott, LCSW for more information.

 

Memory Impaired Longitudinal Study

Description

This is the primary research study at the ADRC. Data gathered from this longitudinal study has helped us learn about the clinical development and pathology of the disease. It has also helped us learn to discriminate among the various kinds of dementia, such as Parkinson’s disease, Lewy Body disease, and Pick’s disease (Frontotemporal dementia). We are currently studying pre-clinical and the very earliest stages of the disease. We are able to provide testing to Hispanic, spanish speaking individuals in English and/or Spanish.

Candidate Criteria

Must have a diagnosis of MCI or mild to moderate dementia, a reliable study partner, stable health status, and must not have any history of major strokes.

 

Benefit

Two major benefits are having access to a staff member who evaluate your condition and who will...

(1) inform you of the results of the evaluations and

(2) make suggestions and referrals for coping with problems that you may have

Consultation with our social workers is also available as needed

Cost

There is no financial cost to participate in our longitudinal research study. The only cost to you is in travel, time, and effort involved in an annual evaluation.

You may withdraw at any time. We would, however like a commitment of a minimum of five years in order to gather the optimal longitudinal data.

Time/Procedures

Annual visits that last one and a half days. The annual exam consists of three parts: a nursing exam, a neuropsychological assessment, and a neurology exam. In addition, participants will be asked to undergo a volumetric brain MRI scan and a spinal fluid draw (lumbar punture procedure).

We also request that you agree to a brain autopsy. This is critical to our research, since the pathological confirmation is the only definitive diagnosis for the disease. It also provides tissue for critical studies in the pathophysiology of the disease.

 

[Back to top]